NewAmsterdam Pharma Company N.V. (NAMS) Current Ratio
- Current ratio · latest quarter: Value 9.03×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.03× | Current assets / current liabilities. $659.21M ÷ $72.97M ≈ 9.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 659.21M USD | Assets, Current |
| Current obligations | 72.97M USD | Liabilities, Current |
| Cash and equivalents | 424.15M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 209.70M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 5.42M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $659.21M | $72.97M | $424.15M | $209.70M | (m) | (m) | $5.42M | (m) | 9.03× |
| 2026-03-31 | $658.04M | $67.42M | $457.61M | $178.50M | (m) | (m) | $8.09M | (m) | 9.76× |
| 2025-12-31 | $675.70M | $85.79M | $490.00M | $146.24M | (m) | (m) | $8.97M | (m) | 7.88× |
| 2025-09-30 | $732.33M | $58.27M | $538.41M | $164.54M | (m) | (m) | $3.63M | (m) | 12.57× |
| 2025-06-30 | $769.85M | $36.51M | $563.86M | $175.30M | (m) | (m) | $5.89M | (m) | 21.08× |
| 2025-03-31 | $817.30M | $40.91M | $748.42M | $60.06M | (m) | (m) | $6.09M | (m) | 19.98× |
| 2024-12-31 | $863.41M | $106.92M | $771.74M | $62.45M | (m) | (m) | $4.74M | (m) | 8.08× |
| 2024-09-30 | $437.87M | $41.26M | (m) | (m) | (m) | (m) | $7.04M | (m) | 10.61× |
| 2024-06-30 | $445.35M | $45.31M | (m) | (m) | (m) | (m) | $5.28M | (m) | 9.83× |
| 2024-03-31 | $487.82M | $59.73M | (m) | (m) | (m) | (m) | $8.54M | (m) | 8.17× |
| 2023-12-31 | $346.79M | $49.90M | $340.45M | (m) | (m) | (m) | $16.92M | (m) | 6.95× |
| 2022-12-31 | $477.98M | $36.06M | (m) | (m) | (m) | (m) | $11.85M | (m) | 13.26× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |